Company intelligence / Profile preview

Xias Bio

Glasgow, Scotland, United Kingdomxiasbio.com ↗

Ownership: Private
Employees: ~9
Development stage: Commercial

Overview

Xias Bio has developed a proprietary molecular platform—LiteProtein™—to create animal-free multifunctional proteins with enhanced performance. These are being adopted by cosmetics and personal care companies as sustainable alternatives to animal-derived or single-function recombinant proteins. The company has secured early sales and strong industry interest. No clinical trial results reported; focus currently on industrial/commercial use.

Therapeutic areas: OtherDermatology
Modalities: Recombinant proteinsmultifunctional proteins
Industry: Non-Drug Biotech

Partnerships

Early commercial partnerships with cosmetic ingredient manufacturers and brands integrating LiteProteins into their portfolios.

Beyond the preview

Go deeper on Xias Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xias Bio.

Explore the full profile